DelveInsight has launched a new report on “Primary Immunodeficiency Disease (PIDD) – Market Insights, Epidemiology, and Market Forecast-2030”
DelveInsight’s “Primary Immunodeficiency Disease Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Primary Immunodeficiency Disease (PID), historical and forecasted epidemiology as well as the Primary Immunodeficiency Disease (PID) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some facts of the Report:
- According to Delveinsight’s Analysts, more than 200 different forms of Primary Immunodeficiency Diseases affecting approximately 500,000 people in the United States and these rare genetic diseases may be debilitating, chronic, and costly.
- According to Delveinsight’s estimates, severe combined immunodeficiency (SCID) is a rare genetic disorder, affecting one in 30,000 new borns.
- The Market size of PIDD is expected to increase for the study period of 2017-2030.
- According to Delveinsight, Primary Immunodeficiency Disease Market is expected to grow at a CAGR of XX%.
Report Key Highlights:
- Primary Immunodeficiency Disease market report covers a descriptive overview and comprehensive insight of the PIDD epidemiology and Primary Immunodeficiency Disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- Primary Immunodeficiency Disease market report provides the insights on the current and emerging PIDD therapies.
- Primary Immunodeficiency Disease market report provides global historical and forecasted market covering drug outreach in 7 MM.
- Primary Immunodeficiency Disease market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the Primary Immunodeficiency Disease market.
Request for Sample Page: https://www.delveinsight.com/sample-request/primary-immune-deficiency-pid-market
Primary immunodeficiency disease (PIDD) is a condition in which the immune system is weaker than normal. The term “primary” implies that there is an independent problem of the immune system rather than a weakening of the immune system due to another condition like HIV/AIDS (a secondary immune deficiency).
Primary immunodeficiency disease is most often identified in infants and children, but it is possible that the condition is identified in adulthood. Primary immunodeficiency disease represents a diverse group of hundreds of diseases that can weaken the immune system.
Most often, primary immunodeficiency disease results in increased susceptibility to both acute and chronic (long-term) infections.
The types of primary immunodeficiency disease are far too numerous to list here. Examples of some of the more commonly known primary immunodeficiency diseases include:
- Wiscott-Aldrich syndrome
- Severe combined immunodeficiency disease (SCID)
- DiGeorge syndrome
- Ataxia-telangectasia
- Chronic granulomatous disease
- Transient hypogammaglobulinemia of infancy
- Agammaglobulinemia
- Complement deficiencies
- Selective IgA deficiency
- And Many More
Request for Sample Page: https://www.delveinsight.com/sample-request/primary-immune-deficiency-pid-market
Some of the key companies involved:
- Octapharma
- Takeda
- X4 Pharmaceuticals
- Kedrion
- CSL Behring
- Grifols
- Pfizer
- Shire
- And Many More
Some of the Drugs:
- Cutaquig
- HyQvia
- X4P-001
- 10%IVIG
- PRIVIGEN
- GAMUNEX®-C
- And Many More
Request for Sample Page: https://www.delveinsight.com/sample-request/primary-immune-deficiency-pid-market
Table of contents:
1. Key Insights
2. Executive Summary of Primary Immunodeficiency Disease (PIDD)
3. Competitive Intelligence Analysis for Primary Immunodeficiency Disease (PIDD)
4. Primary Immunodeficiency Disease (PIDD): Market Overview at a Glance
5. Primary Immunodeficiency Disease (PIDD): Disease Background and Overview
6. Patient Journey
7. Primary Immunodeficiency Disease (PIDD) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Primary Immunodeficiency Disease (PIDD) Treatment
11. Marketed Products
12. Emerging Therapies
13. Primary Immunodeficiency Disease (PIDD): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Primary Immunodeficiency Disease (PIDD)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/primary-immune-deficiency-pid-market
Related Reports:
Primary Immunodeficiency Disease (PIDD) – Epidemiology Forecast to 2030
DelveInsight’s ‘Primary Immunodeficiency Disease (PIDD) – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Primary Immunodeficiency Disease (PIDD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Primary Immunodeficiency Disease (PIDD) – Pipeline Insights, 2020
“Primary Immunodeficiency Disease (PIDD) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Immunodeficiency Disease (PIDD) market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/primary-immune-deficiency-pid-market